Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medic

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-t

What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medic

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a prot

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breas

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the an

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the a

– The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive d

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raise

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants wi

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the a

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN t

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in pa

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and r

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS)

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse ra

Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and rais

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on de

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS)

Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost p